Compare iShares MSCI Japan ETF (EWJ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI Japan ETF trades at $97.85, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| EWJ | SANA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $96.97 | $5.92 |
52-Week Low | $77.93 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.79, up 1.81% today, with a bullish technical signal driven by strong moving average alignment. The fund's performance is influenced by Japanese economic policies, including recent U.S.-Japan currency intervention and domestic stimulus efforts. Key resistance sits at $97, with support at $96. Recent news highlights focus on yen strength and its impact on export-heavy Japanese equities.
The outlook for EWJ is cautiously optimistic, supported by bullish technicals and potential economic tailwinds from Japanese fiscal policy. Risks include yen volatility, export sensitivity to currency moves, and broader Asian market turbulence. Investor sentiment is mixed, balancing policy support against inflation and growth concerns.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
